XPhyto Therapeutics Corp. (4XT.DE)

XPhyto Therapeutics Corp. (4XT.DE) — VMCI valuation read

Across 120 indicators, XPhyto Therapeutics Corp. (4XT.DE) lands at VMCI 18/100. The Healthcare sector median is 50, so the 32-point below-median read is the active comparison. Pillar weighting on the score: Value 35%, Quality 30%, Integrity 15%, Growth 12%, Risk 8%.

No material Form 4 disclosures landed on 4XT.DE in the past 30 days. Quiet insider tape removes one signal source; the active reads stay with the trailing-twelve-month financials and the next 10-Q.

**Investor frame.** On Value, 4XT.DE trades at 25.0x earnings, 39% above the Healthcare median of 18.0x; the EV/EBITDA delta of -2.0x reinforces that single line. On Quality, ROIC of 13.0% sits 3.0pp above the Healthcare median (10.0%). On Risk, net debt to EBITDA of -0.6x leaves covenant headroom for 4XT.DE on the trailing balance sheet.

4XT.DE fell 1.4% over the trailing 7 days, with a -0.7% read on a 30-day basis.